bum jun kim

Assistnt professor

Hallym University Sacred Heart Hospital

South Korea

Research Interests

Explore related searches

Professors in South Korea Professors in Cancer Research Cancer Research professors in South Korea

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Bum Jun Kim is an Assistant Professor at Hallym University Sacred Heart Hospital in South Korea. His research focuses on oncology and hematology, particularly in the areas of functional iron-deficiency anemia, breast cancer metastasis prediction, and the efficacy of various treatment combinations in gastrointestinal malignancies. Notable publications include studies on the use of Darbepoetin Alfa and Ramucirumab in cancer therapy, as well as deep learning applications in clinical oncology.

Articles (8)

Year:

2025

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (2)

Jung Hye Kwon

Professor

Chungnam National University School of Medicine

SOUTH KOREA

View details

Hee-Jung Jee

Assistant Professor

Chungbuk National University

SOUTH KOREA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

bum jun kim

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

Effects of Darbepoetin Alfa and Ferric Derisomaltose Plus Darbepoetin Alfa in Functional Iron-Deficiency Anemia

Deep Learning Prediction of Axillary Lymph Node Metastasis in Breast Cancer Patients Using Clinical Implication-Applied Preprocessed CT Images

Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)

A phase II study of chemotherapy in combination with telomerase peptide vaccine (GV1001) as second-line treatment in patients with metastatic colorectal cancer

Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16)

A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer

Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification

The efficacy and safety of onartuzumab in patients with solid cancers: A meta-analysis of randomized trials

Collaborators (2)

Jung Hye Kwon

Hee-Jung Jee

Make your next move.